Explore

Trendline Trendline
Zimmer Biomet Announces CFO Transition Amid Strategic Focus

Zimmer Biomet Announces CFO Transition Amid Strategic Focus

Zimmer Biomet Announces CFO Transition Amid Strategic Focus
Trendline Trendline
Bridgestone Announces Key Executive Leadership Changes in North America

Bridgestone Announces Key Executive Leadership Changes in North America

Bridgestone Announces Key Executive Leadership Changes in North America
Trendline Trendline
Ribbon Communications Promotes Rick Marmurek to Chief Financial Officer, Enhancing Leadership Team

Ribbon Communications Promotes Rick Marmurek to Chief Financial Officer, Enhancing Leadership Team

Ribbon Communications Promotes Rick Marmurek to Chief Financial Officer, Enhancing Leadership Team
Trendline Trendline
Barrick Mining Corporation Announces Executive Team for North American Spin-Off

Barrick Mining Corporation Announces Executive Team for North American Spin-Off

Barrick Mining Corporation Announces Executive Team for North American Spin-Off
Trendline Trendline
Ribbon Communications Promotes Rick Marmurek to Chief Financial Officer, Succeeding John Townsend

Ribbon Communications Promotes Rick Marmurek to Chief Financial Officer, Succeeding John Townsend

Ribbon Communications Promotes Rick Marmurek to Chief Financial Officer, Succeeding John Townsend
Trendline Trendline
CatalYm Appoints Christian S. Schade as Chairman Amid Clinical Advancements

CatalYm Appoints Christian S. Schade as Chairman Amid Clinical Advancements

CatalYm Appoints Christian S. Schade as Chairman Amid Clinical Advancements
Trendline Trendline
Booz Allen Hamilton Appoints New CFO and Elevates Anderson to President

Booz Allen Hamilton Appoints New CFO and Elevates Anderson to President

Booz Allen Hamilton Appoints New CFO and Elevates Anderson to President
Trendline Trendline
Eli Lilly Acquires Ajax Therapeutics for $2.3 Billion, Expanding Blood Cancer Treatment Pipeline

Eli Lilly Acquires Ajax Therapeutics for $2.3 Billion, Expanding Blood Cancer Treatment Pipeline

Eli Lilly Acquires Ajax Therapeutics for $2.3 Billion, Expanding Blood Cancer Treatment Pipeline
Reuters Reuters
Eli Lilly to buy Ajax Therapeutics for up to $2.3 billion in blood cancer bet

Eli Lilly to buy Ajax Therapeutics for up to $2.3 billion in blood cancer bet

By Christy Santhosh April 27 (Reuters) - Eli Lilly said on Monday it would buy privately held cancer drug developer Ajax Therapeutics for up to $2.3 billion in cash, as the U.S. drugmaker looks to expand its oncology pipeline.
Trendline Trendline
Booz Allen Hamilton Appoints New CFO and Elevates Kristine Martin Anderson to President

Booz Allen Hamilton Appoints New CFO and Elevates Kristine Martin Anderson to President

Booz Allen Hamilton Appoints New CFO and Elevates Kristine Martin Anderson to President
Trendline Trendline
ADC Therapeutics to Announce Q1 2026 Financial Results in Upcoming Conference Call

ADC Therapeutics to Announce Q1 2026 Financial Results in Upcoming Conference Call

ADC Therapeutics to Announce Q1 2026 Financial Results in Upcoming Conference Call
Trendline Trendline
Court Ruling Denies GSK/Tesaro's Claim in Jemperli Dispute with AnaptysBio

Court Ruling Denies GSK/Tesaro's Claim in Jemperli Dispute with AnaptysBio

Court Ruling Denies GSK/Tesaro's Claim in Jemperli Dispute with AnaptysBio